Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

ABSTRACT:

Background

In men with metastatic castration-resistant prostate cancer (mCRPC) with primarily bone metastases, radium-223 (²²³ Ra) improves overall survival (OS). However, the selection of ²²³ Ra is not guided by specific validated clinicopathologic factors, and thus outcomes are heterogeneous.

Patients and methods

This retrospective survival analysis was performed in men with mCRPC treated with ²²³ Ra at our cancer center. Demographics and disease characteristics were collected. OS was calculated using the Kaplan-Meier method (log-rank). The potential prognostic factors were determined using both univariable (UVA) and multivariable analysis (MVA) (Cox-regression) methods.

Results

In total, 150 patients with a median age of 74 years (5

SUBMITTER: Al-Ezzi EM 

PROVIDER: S-EPMC8419779 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature